Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.

Danese S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, Jairath V, D'Haens G, Kierkuś J, Leong RW, Yarur AJ, Vincent MS, Banerjee A, Chandra DE, Peeva E, Neelakantan S, Hung KE, McBride JM, Bojic D, Lasch K, Schiffman C, Feagan BG

Open source

DOI: 10.1016/s2468-1253(25)00129-3
Published: 2025 Oct
Container: The lancet. Gastroenterology & hepatology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2468-1253-25-00129-3,
  title = {Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.},
  author = {Danese S and Allegretti JR and Schreiber S and Peyrin-Biroulet L and Jairath V and D'Haens G and Kierkuś J and Leong RW and Yarur AJ and Vincent MS and Banerjee A and Chandra DE and Peeva E and Neelakantan S and Hung KE and McBride JM and Bojic D and Lasch K and Schiffman C and Feagan BG},
  year = {2025},
  journal = {The lancet. Gastroenterology \& hepatology},
  doi = {10.1016/s2468-1253(25)00129-3},
  url = {https://doi.org/10.1016/s2468-1253(25)00129-3}
}

RIS

TY  - JOUR
TI  - Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.
AU  - Danese S
AU  - Allegretti JR
AU  - Schreiber S
AU  - Peyrin-Biroulet L
AU  - Jairath V
AU  - D'Haens G
AU  - Kierkuś J
AU  - Leong RW
AU  - Yarur AJ
AU  - Vincent MS
AU  - Banerjee A
AU  - Chandra DE
AU  - Peeva E
AU  - Neelakantan S
AU  - Hung KE
AU  - McBride JM
AU  - Bojic D
AU  - Lasch K
AU  - Schiffman C
AU  - Feagan BG
PY  - 2025
JO  - The lancet. Gastroenterology & hepatology
DO  - 10.1016/s2468-1253(25)00129-3
UR  - https://doi.org/10.1016/s2468-1253(25)00129-3
ER  -

APA

S, D., JR, A., S, S., L, P., V, J., G, D., J, K., RW, L., AJ, Y., MS, V., A, B., DE, C., E, P., S, N., KE, H., JM, M., D, B., K, L., C, S., & BG, F. (2025). Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.. The lancet. Gastroenterology & hepatology. https://doi.org/10.1016/s2468-1253(25)00129-3

Source records

pubmed · retrieved 2026-09-26T12:58:39.395Z
europe-pmc · retrieved 2026-09-26T12:58:39.447Z